




PHARMACEUTICAL 2018

Neos Therapeutics Inc.
Rank 276 of 342





PHARMACEUTICAL 2018

Neos Therapeutics Inc.
Rank 276 of 342

The relative strengths and weaknesses of Neos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neos Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 32% points. The greatest weakness of Neos Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -51%, being 97% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	82,640
Cost of Goods Sold	12,391
Intangible Assets	16,348
Liabilities, Current	37,602
Liabilities, Non-Current	61,861
Other Assets	162
Other Compr. Net Income	-5.0
Other Expenses	46,881
Other Liabilities	0
Other Net Income	-9,231
Other Revenues	25,018
Property and Equipment	8,203
Research and Development	8,957
Selling, General and Administrative Expense	13,805

Output Variable	Value in 1000 USD
Assets	107,353
Liabilities	99,463
Expenses	82,034
Revenues	25,018
Stockholders Equity	7,890
Net Income	-66,247
Comprehensive Net Income	-66,250
Economic Capital Ratio	-51%